Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CytomX Therapeutics (NASDAQ: CTMX) announced that its CEO, Sean McCarthy, will present at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 11:00 a.m. ET. The presentation will be broadcast live on CytomX's website, allowing investors to attend through a one-on-one meeting format. CytomX, focused on developing innovative conditionally activated biologics for cancer treatment, showcases technologies such as its Probody® platform and has a robust pipeline, including CX-2029, an ADC targeting CD71, and partnerships with leading pharma companies like Bristol Myers Squibb and Amgen. These advancements aim to improve treatment standards in oncology.
CytomX Therapeutics reported its financial results for 2022 and outlined significant advancements in its therapeutic pipeline, including the ongoing Phase 1 study for CX-904, a T-cell engaging bispecific therapy, and anticipated IND filings for CX-2051 and CX-801 later this year. The company highlighted collaborations with Bristol Myers Squibb, Moderna, and Regeneron, aiming to bolster its strategy and funding. Financially, total revenue for 2022 rose to $53.2 million, up from $37.3 million in 2021. However, cash reserves decreased to $194 million at year-end. CytomX is prioritizing ongoing clinical studies and reassessing its CX-2029 program following AbbVie’s decision to terminate its collaboration.
CytomX Therapeutics (Nasdaq: CTMX) announced it will release its full year 2022 financial results on March 27, 2023, after U.S. market close. The company will follow up with a conference call at 5:00 p.m. ET to discuss the results. Investors can access the live webcast on the company’s website and are encouraged to register 10 minutes prior to the call. CytomX is focused on developing conditionally activated biologics for cancer treatment, with a robust pipeline including collaborations with major partners like AbbVie and Bristol Myers Squibb.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced CEO Sean McCarthy's participation in March investor conferences. He will speak at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. ET in Boston, MA, and at the Barclays Global Healthcare Conference on March 14, 2023, at 4:05 p.m. ET in Miami, FL. Live webcasts of these events will be available on CytomX's website. CytomX focuses on conditionally activated biologics for cancer treatment, with a diverse pipeline, including collaborations with AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (CTMX) has achieved a significant milestone by progressing its first Probody® TCB clinical candidate in collaboration with Astellas, triggering a $5 million milestone payment. This marks an important step in their multi-target collaboration, where CytomX retains U.S. co-commercialization and economic rights for select programs. The CEO emphasized the potential of localized T-cell engaging therapies to revolutionize cancer treatment. CytomX is advancing a diverse pipeline of seven therapeutic candidates, including T-cell engaging bispecific antibodies and antibody-drug conjugates, further enhancing its position in the oncology market.